TY - JOUR T1 - Natural killer cell activation related to clinical outcome of COVID-19 JF - medRxiv DO - 10.1101/2020.07.07.20148478 SP - 2020.07.07.20148478 AU - Christopher Maucourant AU - Iva Filipovic AU - Andrea Ponzetta AU - Soo Aleman AU - Martin Cornillet AU - Laura Hertwig AU - Benedikt Strunz AU - Antonio Lentini AU - Björn Reinius AU - Demi Brownlie AU - Angelica Cuapio Gomez AU - Eivind Heggernes Ask AU - Ryan M. Hull AU - Alvaro Haroun-Izquierdo AU - Marie Schaffer AU - Jonas Klingström AU - Elin Folkesson AU - Marcus Buggert AU - Johan K. Sandberg AU - Lars I. Eriksson AU - Olav Rooyackers AU - Hans-Gustaf Ljunggren AU - Karl-Johan Malmberg AU - Jakob Michaëlsson AU - Nicole Marquardt AU - Quirin Hammer AU - Kristoffer Strålin AU - Niklas K. Björkström AU - Karolinska COVID-19 Study Group Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/10/2020.07.07.20148478.abstract N2 - Understanding innate immune responses in COVID-19 is important for deciphering mechanisms of host responses and interpreting disease pathogenesis. Natural killer (NK) cells are innate effector lymphocytes that respond to acute viral infections, but might also contribute to immune pathology. Here, using 28-color flow cytometry, we describe a state of strong NK cell activation across distinct subsets in peripheral blood of COVID-19 patients, a pattern mirrored in scRNA-seq signatures of lung NK cells. Unsupervised high-dimensional analysis identified distinct immunophenotypes that were linked to disease severity. Hallmarks of these immunophenotypes were high expression of perforin, NKG2C, and Ksp37, reflecting a high presence of adaptive NK cell expansions in circulation of patients with severe disease. Finally, arming of CD56bright NK cells was observed in course of COVID-19 disease states, driven by a defined protein-protein interaction network of inflammatory soluble factors. This provides a detailed map of the NK cell activation-landscape in COVID-19 disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Swedish Research Council, the Swedish Cancer Society, the Swedish Foundation for Strategic Research, Knut and Alice Wallenberg Foundation, Nordstjernan AB, the Center for Innovative Medicine at Karolinska Institutet, Region Stockholm, SRP Diabetes Karolinska Institutet, StratRegen Karolinska Institutet, and Karolinska Institutet. IF and CM are funded by the Wenner-Gren Foundations and QH is supported by the European Molecular Biology Organization (EMBO ALTF 802-2018).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Swedish Ethical Review Authority.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCurated flow cytometry data is available for exploration via the Karolinska COVID-19 Immune Atlas (homepage currently under construction). ER -